BioVie CEO on Parkinson's, Long COVID, and Liver Disease Trials

BioVie's Parkinson's Disease Trial

• 💡 BioVie's drug candidate, Bezyum, is being evaluated in a fully enrolled Phase 1 trial with 60 Parkinson's patients.
• 🎯 The trial aims to assess Bezyum's impact on both motor and non-motor symptoms of Parkinson's, including sleep, cognition, and mood.
• 🧠 Unlike current treatments that focus on dopamine, Bezyum targets neuroinflammation and insulin resistance, potentially allowing the body to better utilize existing dopamine.
• 🚀 Preclinical studies suggest Bezyum may be disease-modifying by preserving neurons, a critical aspect for a neurodegenerative disease.
• 📈 Top-line data from the Parkinson's trial is anticipated in May.

Addressing Long COVID Symptoms

• 💬 Bezyum's mechanism of action, which involves reducing TNF alpha and inflammation, is believed to be relevant for Long COVID symptoms.
• 🧠 Symptoms like brain fog, fatigue, and cognitive issues in Long COVID are also linked to inflammation, similar to Parkinson's.
• 🔬 Leading medical centers including Mount Sinai, Mayo Clinic, Yale, UCSF, and Stanford are participating in the Long COVID trial.
• ✅ Results from the Long COVID trial are expected around mid-summer.

Advancing Liver Disease Treatment

• ⚠️ BioVie is preparing to launch a Phase 3 trial for ascites, a severe end-stage liver disease with a high mortality rate.
• ⚡ Bezyum (BIV0201) has the potential to be the first therapy for ascites, a condition currently lacking effective treatments.
• 🗓️ The company is working on financing to initiate this trial later in the year, positioning 2026 as a catalyst-driven year across multiple indications.